European Urology
Volume 51, Issue 2 , Pages 473-478 , February 2007

Impact of LUTS Using Bother Index in DAN-PSS-1 Questionnaire

  • Jukka T. Häkkinen

      Affiliations

    • Department of Urology, Tampere University Hospital, Tampere, Finland
    • Corresponding Author InformationCorresponding author. Department of Urology, Tampere University Hospital, PO Box 2000, FIN-33521 Tampere, Finland. Tel. +358 40 570 5786; Fax: +358 3 3116 4358.
    • ,
  • Matti Hakama

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Heini Huhtala

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Rahman Shiri

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Anssi Auvinen

      Affiliations

    • School of Public Health, University of Tampere, Tampere, Finland
    • ,
  • Teuvo L.J. Tammela

      Affiliations

    • Department of Urology, Tampere University Hospital, Tampere, Finland
    • Medical School, University of Tampere, Tampere, Finland
    • ,
  • Juha Koskimäki

      Affiliations

    • Department of Urology, Tampere University Hospital, Tampere, Finland

,Accepted 7 June 2006.

References 

  1. Boyarsky S, Jones G, Paulson DF, Prout GR. A new look at bladder neck obstruction by food administration regulators: guidelines for the investigation of benign prostatic hyperplasia. Trans Am Assoc Genitourin Surg. 1977;68:29–32
  2. Madsen PO, Iversen P. A point system for selecting operative candidates. In:  Hinman F editors. Benign Prostatic Hypertrophy. New York: Springer; 1983;p. 763–765
  3. Mebust W, Roizo R, Schröder FH, Villiers A. Correlation between pathology, clinical symptoms and the course of the disease. In:  Cockett ATK,  Aso Y,  Chatelain C, et al. editor. The International Consultation on Benign Prostatic Hyperplasia (BPH). SCI; 1991;p. 53–62
  4. Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, Walter SA. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol. 1991;138:59–62
  5. Barry MJ, Fowler FJ, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. Med Care. 1995;33:AS145–AS155
  6. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJMCH. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol. 2004;46:547–554
  7. Engström G, Walker-Engström ML, Henningsohn L, Loof L, Leppert J. Prevalence of distress and symptom severity from the lower urinary tract in men: a population-based study with the DAN-PSS questionnaire. Fam Pract. 2004;21:617–622
  8. Eckhardt MD, van Venrooij GE, van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol. 2001;166:563–568
  9. Perrin P, Marionneau N, Cucherat M, Taieb C. Relationship between lower urinary tract symptoms frequency assessed by the IPSS and bothersomeness (SPI) among men older than 50 years old. Eur Urol. 2005;48:601–607
  10. Hansen BJ, Flyger H, Brasso K, et al. Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol. 1995;76:451–458
  11. Kay L, Stigsby B, Brasso K, Mortensen SO, Munkgaard S. Lower urinary tract symptoms. A population survey using the Danish Prostatic Symptom Score (DAN-PSS) questionnaire. Scand J Urol Nephrol. 1999;33:94–99
  12. Koskimäki J, Hakama M, Huhtala H, Tammela TLJ. Prevalence of lower urinary tract symptoms in Finnish men: a population-based study. Br J Urol. 1998;81:364–369
  13. Hansen BJ, Flyger H, Mortensen SO, Mensink HJA, Meyhoff H-H. Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Scand J Urol Nephrol. 1995;30:103–107
  14. Meyhoff HH, Hald T, Nordling J, Andersen JT, Bilde T, Walter S. A new patient weighted symptom score system (DAN-PSS-1). Clinical assessment of indications and outcomes of transurethral prostatectomy for uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol. 1993;27:493–499
  15. Shiri R, Koskimäki J, Hakama M, et al. Prevalence and severity of erectile dysfunction in 50 to 75-year-old Finnish men. J Urol. 2003;170:2342–2344
  16. Peters TJ, Donovan JL, Kay HE. The International Continence Society ‘BPH’ study: the bothersomeness of urinary symptoms. J Urol. 1997;157:885–889
  17. Brown CT, O’Flynn E, Van Der Meulen J, Newman S, Mundy AR, Emberton M. The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened?. BJU Int. 2003;91:30–32
  18. Asplund R. Nocturia: consequences for sleep and daytime activities and associated risks. Eur Urol Suppl. 2005;3(6):24–32

PII: S0302-2838(06)00719-6

doi: 10.1016/j.eururo.2006.06.011

European Urology
Volume 51, Issue 2 , Pages 473-478 , February 2007

Article Tools

* Image Usage & Resolution